PDF

J Cancer 2021; 12(6):1729-1733. doi:10.7150/jca.51190 This issue Cite

Research Paper

Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α5 in pancreatic stellate cells

Tao Wang, Ye Peng, Rou Li, Xiao Li, Changjing Zuo

Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai 200433, China.

✉ Corresponding author: Changjing Zuo, E-mail: cjzuoedu.cn.

Abstract

Background: Integrin α5 (ITGA5) is overexpressed specifically in pancreatic cancer stroma, specially, in the activated pancreatic stellate cells (PSCs). Molecular imaging of pancreatic cancer via targeting PSCs has its advantages.

Purpose: This study aims to investigate the feasibility of ITGA5-targeted SPECT/CT imaging of pancreatic cancer by targeting PSCs.

Methods: ITGA5 expression in PSCs treated without or with pancreatic cancer SW1990 cells conditioned medium (SW1990-CM) was assessed by western blotting and immunofluorescence staining. ITGA5 specific inhibitor AV3 peptide was radiolabeled with ¹²⁵I to synthesize ¹²⁵I-AV3, and the labeling rate, in vitro stability and cellular uptake were further investigated. SW1990 cells alone or with PSCs were injected subcutaneously on the left and right lower limbs of nude mice respectively to establish pancreatic cancer xenograft model, and then ¹²⁵I-AV3 SPECT/CT imaging of pancreatic cancer-bearing nude mice was performed. The expression of ITGA5 in tumors was detected by immunohistochemical (IHC) staining.

Results: ¹²⁵I-AV3 has an excellent labeling rate and good in vitro stability. After treated with SW1990-CM, PSCs had an increased expression of ITGA5 and higher ¹²⁵I-AV3 uptake. SPECT/CT imaging study showed that ¹²⁵I-AV3 was mainly accumulated in the right xenografts (co-injection of cancer cells and PSCs), while the left xenografts tumors have a poor imaging. Moreover, the uptake of radiotracer in both side tumors was inhibited significantly after the non-radiolabeled AV3 pretreatment. IHC staining showed that SW1990 + PSCs tumor has a higher positive rate of ITGA5 than SW1990 tumor.

Conclusion: The preliminary study suggests that ¹²⁵I-AV3 can be used for SPECT/CT imaging of pancreatic cancer via targeting ITGA5 in PSCs, which is independent of the state of cancer cells and may have a special meaning.

Keywords: pancreatic cancer, SPECT imaging, pancreatic stellate cells, integrin α5, targeting

Introduction

Pancreatic cancer remains one of the most aggressive and the least curable cancers, whose mortality is approximately equal to incidence. Nuclear medicine molecular imaging techniques such as single photo emission computed tomography (SPECT) and positron emission tomography (PET), which are quite different from the anatomical imaging including ultrasonography, CT and MRI, can provide the functional information based on the metabolic characteristics or specific biomarker of tumor, and have been widely used in preclinical or clinical diagnosis and management of pancreatic cancer [1]. Specially, the clinical used ¹⁸F-FDG PET/CT and PET/MR have showed excellent performances for the initial staging, treatment plan determination, therapy response and prognosis evaluation of pancreatic cancer, and contribute to improve the tumor outcome [2-4]. However, ¹⁸F-FDG PET/CT still has several drawbacks in detecting pancreatic cancer. The chronic and acute pancreatitis both have high ¹⁸F-FDG uptake, leading to false-positive interpretations, and the application of ¹⁸F-FDG PET in hyperglycemic patients also is not ideal, because the uptake of imaging agent is suppressed as a result of high serum glucose competitive inhibition [5,6]. Therefore, the development of new molecular probes, which can target pancreatic cancer specifically and overcome the limitations of ¹⁸F-FDG to some extent, are urgently needed and have great clinical significance. For example, integrin α_vβ₆ is specifically overexpressed in pancreatic cancer, and its targeting peptide has been radiolabeled with ^99mTc or ⁶⁸Ga for the SPECT or PET imaging of pancreatic cancer respectively [7,8].

In human pancreatic cancer, the tumor stroma comprised of CAFs, inflammatory cells, blood vessels and extracellular matrix (ECM), can occupy up 90% of the entire tumor mass. PSCs, which are in a quiescent state in the healthy pancreas, but become activation under various kinds of stimuli including inflammatory and carcinogenic processes, are considered as the main source for CAFs and the most prominent cell type of pancreatic cancer stroma [9]. A recent study suggests that ITGA5 is overexpressed specifically in the tumor stroma of pancreatic cancer (mainly in CAFs or the activated PSCs), but has a low to negligible expression in cancer cells or normal pancreas [10]. The overexpression of ITGA5 makes it a promising target for pancreatic cancer imaging by targeting tumor stroma, CAFs or activated PSCs. Considering that the high clinical heterogeneity of cancer cells, CAFs-targeted imaging of various cancers including pancreatic cancer has attracted special interest, especially the emergence of ⁶⁸Ga-FAPI, which targets the roots of the tumor microenvironment rather than the cancer cells themselves and has a high potential to avoid some limitation existed in ¹⁸F-FDG [11,12].

In our preliminary study, we try to investigate the feasibility of SPECT/CT imaging of pancreatic cancer by targeting ITGA5 in PSCs using ¹²⁵I-labeled ITGA5 inhibitor AV3 peptide as the imaging agent. The pancreatic cancer xenografts animal model was established through the con-injection of cancer cells and PSCs, which is more consistent with the clinical pathological characteristics of human pancreatic cancer. This study offers a possibility for pancreatic cancer imaging research via targeting the stroma cell (e.g. PSCs), which is independent on the status of cancer cells and helpful to overcome the heterogeneity of cancer cells.

Methods

Materials and regents

The human pancreatic cancer SW1990 cells and PSCs were obtained from Tongpai (Shanghai) Biotechnology Co., LTD. Anti-ITGA5 antibody and FITC-labeled secondary antibody were purchased from Beijing Bioss Biotechnology Co., LTD. DMEM and fetal bovine serum (FBS) were purchased from Gibco Life Technology Co., LTD. The AV3 peptide (purity = 98.86%) were synthesized by ChinaPeptide Co., Ltd. Na¹²⁵I solution was obtained from Shanghai Xinke Pharmaceutical Company. Iodogen tubes pre-coated with iodogen were purchased from Shanghai Nice-labeling Biotech Co., Ltd. Other common regents were commercially available.

Cell culture and cell experiments

SW1990 cells and PSCs were cultured in DMEM containing 10% FBS at 37 °C in a 5% CO₂ incubator. For the preparation of SW1990-CM, SW1990 cells in a 10-cm dish were washed twice with PBS and then cultured with DMEM (10 mL) without FBS for 48 h. Then, the supernatant was centrifuged for 10 min at 3000 rpm at 4 °C, filtrated with 0.22 μm filters and eventually collected as SW1990-CM. To observe the influence of the tumor microenvironment on the ITGA5 expression of PSCs, when PSCs reached about 80% confluence, the medium was replaced by DMEM (as control group) or SW1990-CM and continue to culture for 12 h, and then ITGA5 was detected by western blotting and cell immunofluorescence staining.

For western blotting, PSCs were washed twice with PBS and then lysed using RIPA lysis buffer. After the measurement of the protein concentration using BCA assay, the protein lysates were separated by 10% SDS-PAGE and then transferred to a PVDF membrane. The membrane was blocked with 5% non-fat milk for 1 h in TBST at room temperature. After this, following the recommended concentration, the PVDF membranes were incubated with anti-ITGA5 antibody or GAPDH monoclonal antibody overnight at 4 °C, followed by HRP-conjugated secondary antibody at room temperature for 1 h. Lastly, the membrane was rinsed twice with TBST, and the bands of membrane were visualized using Tanon 5200 chemiluminescence detection system. The relative density of target bands, which represents the expression level of ITGA5, was quantified using Image J software. The immunofluorescence staining experiment was performed following our previous description [13].

Synthesis and in vitro stability test of ¹²⁵I-AV3

AV3 peptide (RYYRITY), which contains three tyrosine residues, meaning it is very suitable for radioiodine labeling, was radiolabeled with ¹²⁵I using the Iodogen method similar with our previous reported procedures [13]. The mixture of 20 μg AV3 peptide (dissolved in 200 μL water) and 2 mCi Na¹²⁵I were added into an Iodogen tube containing 50 μg Iodogen, and about 10 min later, the reaction was ended by separating the supernatant (¹²⁵I-AV3) and iodogen. The labeling rate of ¹²⁵I-AV3 was measured using a mini-scan radio thin layer chromatography (TLC) scanner where Xinhua No.1 chromatography filter paper and water were employed as the stationary phase and the mobile phase respectively. The labeling rate can be calculated according to the quantification result of radioactive bands with the help of the system software. For the in vitro stability test, ¹²⁵I-AV3 was mixed with PBS or 10% FBS firstly, and then at different time points (0.5, 1, 4, 8, 12, 24 h), the radiochemical purity (RCP) of ¹²⁵I-AV3 solution in PBS or 10% FBS were assessed following the above-described TLC method.

Cellular uptake of ¹²⁵I-AV3

The cellular uptake difference of ¹²⁵I-AV3 between PSCs and SW1990-CM-treated PSCs was compared. PSCs or SW1990-CM-treated PSCs were seeded in a 6-well plate at a density of 2 × 10⁵ cells/well, and about 50 μCi ¹²⁵I-AV3 was added into each well. Cells were further cultured at 4 °C for 0.5 h, 2 h or 4 h, and at each time point the free ¹²⁵I-AV3 was removed by washing cells twice with PBS. Then, 0.1 M NaOH was added to solubilize the cells, and the cell-bound radioactivity (counts per minute, CPM) of well was measured using a γ-counter.

Establishment of pancreatic cancer xenograft model, SPECT/CT imaging and ITGA5 IHC staining

Six-week-old nude mice were provided by the Laboratory Animal Center of Naval Medical University, and all animal procedures were conducted in accordance with the institutional guidelines. To establish pancreatic cancer-bearing animal model, 100 μL SW1990 cells suspension (1 × 10⁶ cells) alone or with PSCs (5 × 10⁶ cells) were subcutaneously injected into the left and right lower limbs of nude mice respectively. The tumors were observed and when the diameters of tumors exceeded 1.0 cm, the imaging study began. The nude mice were anesthetized and received an injection of 1 mCi ¹²⁵I-AV3 by tail vein. SPECT/CT imaging of pancreatic cancer-bearing nude mice was typically performed at 4 h after injection using a clinical used SPECT/CT scanner (Symbia T16, Siemens, Germany). For the in vivo blocking experiment, excessive non-radiolabeled AV3 (about 100 times) was injected prior to the injection of ¹²⁵I-AV3, and then SPECT/CT imaging was carried out. The co-registration of SPECT and CT images were performed and the fusion images were quite visually intuitive to assess the radiotracer uptake in tumors.

After imaging, pancreatic cancer-bearing nude mice were executed with overdose anesthesia and the tumors in both lower limbs were cut off, and then ITGA5 expression in tumors was assessed by IHC staining in accordance with the corresponding protocols.

Statistical analysis

Quantitative data are expressed as the means ± SD, and the difference between two groups was compared by student t-test using GraphPad Prism 5 software. P < 0.05 was considered statistically significant.

Results

SW1990-CM promoted the expression of ITGA5 in PSCs

Inside pancreatic cancer, the tumor microenvironment induces PSCs activation, and the activated PSCs are the major contributor to the malignant biological behavior of pancreatic cancer. Cancer cell conditioned medium often is chosen to mimic this microenvironment. In present study, according to the results from Figure 1, after the treatment with SW1990-CM, ITGA5 expression in PSCs has a significant increase, meaning that PSCs activation occurred and our used pancreatic cancer xenografts, which were established by the co-injection of cancer cells and PSCs, would have a high expression of ITGA5 in the tumor stroma or the activated PSCs.

 Figure 1 

Western blotting assay (A) and cell immunofluorescence staining (B) of ITGA5 expression in PSCs without or with SW1990-CM treatment. *P < 0.05, n = 3.

 Figure 2 

The labeling rate (A), in vitro stability (B) and cellular uptake (C) of ¹²⁵I-AV3. *P < 0.05, n = 3.

The in vitro stability and cellular uptake of ¹²⁵I-AV3

An excellent labeling rate (over 98%) of ¹²⁵I-AV3 makes it can be used directly without further purification (Figure 2A). As for the in vitro stability, at the first 4 h, the de-iodination of the radiotracer was very slowly, and up to 12 h after incubation, the radiochemical purity of ¹²⁵I-AV3 still reached 91%, 82% in PBS and 10% FBS, respectively, suggesting a not outstanding but still good in vitro stability (Figure 2B). As shown in Figure 2C, the ¹²⁵I-AV3 uptake in the quiescent and activated PSCs both increased over time, but at each time point, the CPM in SW1990-CM-treated group was higher than that in control group, which can be attributed to a higher expression of ITGA5 in the activated PSCs.

SPECT/CT imaging of pancreatic cancer by targeting PSCs

Given that the activated PSCs play a vital role in the development and progress of pancreatic cancer, co-injection of SW1990 cells and PSCs was adopted to establish the pancreatic cancer xenografts model in our study, and the formed tumors have bigger size compared with SW1990 cells injection alone (Figure 3A). ¹²⁵I-AV3 SPECT/CT imaging of pancreatic cancer-bearing nude mice showed that the radiotracer was mainly accumulated in the right tumor, and the xenografts tumor in the left lower limb has a very weak imaging, suggesting that ¹²⁵I-AV3 can target the ITGA5-expressing PSCs rather than cancer cells (Figure 3A). In blocking experiment, the uptake of radiotracer in both side tumors was inhibited significantly due to the pretreatment with excessive non-radiolabeled AV3 peptide, indicating that the binding of ¹²⁵I-AV3 and ITGA5 is specific in vivo (Figure 3B). In addition, IHC staining further confirmed the tumor status, in which SW1990 + PSCs tumor has a higher positive rate of ITGA5 than SW1990 tumor (Figure 3C).

Discussion

The activated PSCs constitute over 50% of the tumor stroma in pancreatic cancer, and also are the most important stroma cell type and the main source of CAFs [9]. In the field of nuclear medicine molecular imaging, the targeted SPECT and PET imaging of pancreatic cancer is often based on the specific biomarkers expressed in cancer cells (e.g. integrin α_vβ_6, tissue factor, neurotensin receptor 1) or neo-vascularendothelial cells (e.g. integrin α_vβ₃), but few researches focus on the CAFs or PSCs [8,14-16]. However, given that cancer cells constitute a minority but with a high heterogeneity in pancreatic cancer, targeting CAFs or the activated PSCs has its unique advantages and has become one of the research hotspots [17,18].

 Figure 3 

Representative ¹²⁵I-AV3 SPECT/CT imaging at 4 h (A), corresponding SPECT/CT imaging with a blocking dose of AV3 (B) and ITGA5 IHC staining (C) of pancreatic cancer xenografts in nude mice. The xenografts tumors in nude mice were established using SW1990 cells injection alone in the left lower limb (indicated by asterisk) or SW1990 + PSCs co-injection in the right lower limb (indicated by arrow). Pancreatic cancer-bearing nude mice were injected about 1 mCi ¹²⁵I-AV3 from tail vein before the imaging study. Repeated experiments showed similar results.

ITGA5 is an interesting integrin receptor, which is overexpressed specifically in pancreatic cancer stroma and, further, CAFs or the activated PSCs [10]. Consistent with previous reports that cancer cells-conditioned medium induce PSCs activation and enhance the expression of ITGA5 in PSCs [10,19], our in vitro results showed that the expression of ITGA5 in PSCs increased because of the indirect effect of cancer cells, which is the foundation of SPECT imaging of pancreatic cancer. In our study, different from the most common strategy of targeting pancreatic cancer cells, CAFs or the activated PSCs-targeted SPECT/CT imaging of pancreatic cancer was achieved using the ITGA5-targeted molecular probe ¹²⁵I-AV3. The pancreatic cancer xenograft model usually is established by the injection of cancer cells alone, but the important role of stroma cells (e.g. CAFs or PSCs) is grossly neglected, which is inconsistent with human tumor and also is one of the reasons that many laboratory results fail to translate for clinical practice. Our used pancreatic cancer animal model, which was established via cancer cells injection alone and the co-injection of cancer cells and PSCs in the same nude mouse, not only reflected the pro-tumorigenic effect of PSCs, but also confirmed that the existence of PSCs made the xenograft tumor has a higher ITGA5 expression and ITGA5-expressing PSCs rather than cancer cells had an effective uptake of ¹²⁵I-AV3, suggesting the feasible of pancreatic cancer imaging by targeting CAFs or the activated PSCs.

As a preliminary study, the feasibility of ¹²⁵I-AV3 SPECT/CT imaging of pancreatic cancer by targeting ITGA5-expressing PSCs has been confirmed, but there are still some shortcomings. For example, the radioiodine labeling of AV3 peptide is very simple and efficient, but ¹²⁵I itself is an imperfect SPECT radionuclide compared with other radionuclides such as ^99mTc, together with the application of the clinically used SPECT/CT system rather than the small animal micro-SPECT/CT, resulting in difficult to assess the tissue and organ distributions of ¹²⁵I-AV3 from the low resolution SPECT/CT images. In addition, the in vivo stability of ¹²⁵I-AV3 seems to be unsatisfactory. The selective binding, uptake and stability of linear peptide can be enhanced by cyclization [20], and a cyclic AV3 peptide may be a better choose. Based on the preliminary study, ⁶⁸Ga labeled cyclic AV3 for micro-PET/CT imaging of pancreatic cancer-bearing nude mice is worth investing in further.

In conclusion, our preliminary study suggests that ¹²⁵I-AV3 can be used for SPECT/CT imaging of pancreatic cancer via targeting ITGA5 in PSCs, which is independent of the state of cancer cells and may have a special meaning.

Acknowledgements

This work is supported by National Natural Science Foundation of China (82001867) and the Staring Foundation for Young Researcher of Shanghai Changhai Hospital (CH201714).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Cornelissen B, Knight JC, Mukherjee S, Evangelista L, Xavier C, Caobelli F. et al. Translational molecular imaging in exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2018;45:2442-2455

2. Ren S, Zhu X, Zhang A, Li D, Zuo C, Zhang H. Prognostic value of ¹⁸F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. Cancer Imaging. 2020;20:22

3. Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The Role of ¹⁸F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Abdom Radiol (NY). 2018;43:415-434

4. Panda A, Garg I, Johnson GB, Truty MJ, Halfdanarson TR, Goenka AH. Molecular radionuclide imaging of pancreatic neoplasms. Lancet Gastroenterol Hepatol. 2019;4:559-570

5. Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol. 2016;8:165-172

6. Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD. et al. The impact of infection and inflammation in oncologic ¹⁸F-FDG PET/CT imaging. Biomed Pharmacother. 2019;117:109168

7. Liu Z, Liu H, Ma T, Sun X, Shi J, Jia B. et al. Integrin α_vβ₆-Targeted SPECT Imaging for Pancreatic Cancer Detection. J Nucl Med. 2014;55:989-994

8. Feng X, Wang Y, Lu D, Xu X, Zhou X, Zhang H. et al. Clinical Translation of a ⁶⁸Ga-labeled Integrin α_vβ₆-targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer. J Nucl Med. 2020;61:1461-1467

9. Schnittert J, Bansal R, Prakash J. Targeting Pancreatic Stellate Cells in Cancer. Trends Cancer. 2019;5:128-142

10. Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J. et al. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Sci Adv. 2019;5:eaax2770

11. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W. et al. ⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60:801-805

12. Siveke JT. Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment. J Nucl Med. 2018;59:1412-1414

13. Pan G, Li D, Li X, Peng Y, Wang T, Zuo C. SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using ¹²⁵I-Herceptin. Biochem Biophys Res Commun. 2018;504:765-770

14. Yoshimoto M, Hayakawa T, Mutoh M, Imai T, Tsuda K, Kimura S. et al. In vivo SPECT imaging with ¹¹¹In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. J Nucl Med. 2012;53:765-771

15. Ferreira CA, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E. et al. ^86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Mol Pharm. 2020;17:1697-1705

16. Renard E, Dancer PA, Portal C, Denat F, Prignon A, Goncalves V. Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer. J Med Chem. 2020;63:2426-2433

17. Zhang YF, Jiang SH, Hu LP, Huang PQ, Wang X, Li J. et al. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Chin Clin Oncol. 2019;8:18

18. Jiang H, Wang S, Zhou X, Wang L, Ye L, Zhou Z. et al. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. J Control Release. 2018;286:254-263

19. Masamune A, Yoshida N, Hamada S, Takikawa T, Nabeshima T, Shimosegawa T. Exosomes derived from pancreatic cancer cells induce activation and profibrogenic activities in pancreatic stellate cells. Biochem Biophys Res Commun. 2018;495:71-77

20. Roxin A, Zheng G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med Chem. 2012;4:1601-1618

Author contact

Corresponding author: Changjing Zuo, E-mail: cjzuoedu.cn.

Received 2020-7-27
Accepted 2020-12-26
Published 2021-1-18

Citation styles

©2024 Ivyspring International Publisher. Terms of use